Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids
article
OA: closed
CC0
⤵ 13 in-corpus citations
AI-generated summary
Ulipristal acetate treatment for presumed uterine fibroids in adenomyosis patients worsened ultrasound features and increased pelvic pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ulipristal acetate (UPA) is used for medical treatment of uterine fibroids. The aim of this study was to describe the effects on painful symptoms and the sonographic uterine modifications in patients with adenomyosis erroneously treated with UPA. This is an observational study on six women affected by adenomyosis and treated with three months of UPA (5 mg/24h). The baseline ultrasonography (US) was not performed at out center nor was the diagnosis of fibroids. The patients came to our attention after the treatment with UPA, prescribed by an external physician. During our post-treatment scan we found aspects of adenomyosis, while no fibroids were detected. Symptoms, myometrial and endometrial ultrasound features were evaluated. All patients reported an increase in pelvic pain. At US evaluation intramyometrial cystic areas were found in all six cases (100%). All patients showed an enhancement of adenomyosis features.The intra-myometrial cysts appeared enlarged and the vascularization enhanced when compared to the images of the pretreatment scan. In patients with adenomyosis treated with UPA due to an erroneous diagnosis of uterine fibroids we observed a worsening of the US features of adenomyosis and of the painful symptoms.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (14)
- Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis via openalex
- Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. via openalex
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator via openalex
- Limitations of transvaginal sonography for the diagnosis of adenomyosis, with histopathological correlation via openalex
- Pathophysiology of adenomyosis via openalex
- Structural and molecular features of the endomyometrium in endometriosis and adenomyosis via openalex
- Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group via openalex
- Transvaginal sonography in the diagnosis of adenomyosis: which findings are most accurate? via openalex
- Transvaginal ultrasound for diagnosis of adenomyosis: a review via openalex
- W2026392453 via openalex
- W2129011466 via openalex
- W2163946488 via openalex
- W2496662864 via openalex
- W2529996311 via openalex
Cited by (13)
- Drug development for adenomyosis based on pathophysiology 2025
- Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review 2024
- Deep Infiltrating Endometriosis in Adolescence: Early Diagnosis and Possible Prevention of Disease Progression 2024
- The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review 2023
- Medical Treatment of Adenomyosis 2022
- Anti-Mullerian Hormone (AMH) and adenomyosis: Mini-review of literature of the last 5 years 2022
- The Effect of Ulipristal Acetate on Surgical Endometriosis Created in Rats 2022
- Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists 2021
- Current and Prospective Treatment of Adenomyosis 2021
- Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration 2021
- Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids 2020
- Ulipristal Acetate Prior to Surgery for Endometriosis 2020
- Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis 2020
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:19:31.300640+00:00
License: CC0
· commercial use OK